3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Sarcoma
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
36
Cyclophosphamide
24
Nivolumab
23
Ipilimumab
22
aldesleukin
19
Interleukin-2
15
fludarabine
14
Specimen Handling
12
Dacarbazine
11
fludarabine phosphate
10
Magnetic Resonance Spectroscopy
10
Temozolomide
9
Radiosurgery
9
Biopsy
9
cemiplimab
8
Paclitaxel
8
dabrafenib
5
binimetinib
5
Vemurafenib
5
Radiotherapy
5
Carboplatin
5
trametinib
4
sargramostim
4
encorafenib
4
avelumab
4
Pemetrexed
4
Leucovorin
4
Fluorouracil
4
Cisplatin
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
IMM-101
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts